PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC

Trial Details

NCT ID

NCT06419621

Phase

PHASE3

Sponsor

Biotheus Inc.

Status

RECRUITING

Cancer Type

Triple Negative (TNBC) Breast Cancer

Interventions

• PM8002
• Nab-Paclitaxel
• Placebo

Locations (sample)

• Bengbu, Anhui, China|32.94083,117.36083
• Beijing, Beijing Municipality, China|39.9075,116.39723
• Chongqing, Chongqing Municipality, China|29.56026,106.55771
• Fuzhou, Fujian, China|26.06139,119.30611
• Lanzhou, Gansu, China|36.05701,103.83987

Key Eligibility Criteria

• Ability to understand and willing to provide written informed consent and to comply with scheduled visits and study procedures;
• Female, aged 18 to 70 years (inclusive);
• Histologically confirmed unresectable locally advanced or metastatic breast cancer with negative status for ER, PR, and HER-2. Testing results for …
• Subjects who have not received prior systemic treatment（except endocrine therapy） for advanced breast cancer are eligible for the study. Subjects w…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.